ERBB2 and adenocarcinoma: The incidence of Her2 gene mutation in NSCLC is between 2% and 4% [23, 37, 48], and it is more frequent in non-smoker females with Asian ethnicity and adenocarcinoma subtypes similar to those seen in EGFR (Her1) mutations.